Business Context and Reporting Period
Company: CVRx, Inc. (CVRX)
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal year ended December 31, 2025
Business Overview: CVRx is a commercial-stage medical device company focused on neuromodulation solutions for cardiovascular disease. Its primary product, Barostim, is the first FDA-approved device using Baroreflex Activation Therapy (BAT) to improve symptoms in patients with Heart Failure with reduced Ejection Fraction (HFrEF). The company operates primarily in the U.S. and Europe, selling directly to hospitals and through distributors.
Key Financial Metrics
| Metric (in thousands) | 2025 | 2024 |
|---|---|---|
| Revenue | $56,651 | $51,292 |
| Gross Profit | $48,340 | $42,958 |
| Gross Margin | 85% | 84% |
| Net Loss | $(53,306) | $(59,965) |
| Operating Expenses | $99,605 | $102,448 |
| Cash and Cash Equivalents (Year End) | $75,708 | $105,933 |
| Long-Term Debt | $49,514 | $49,273 |
| Accumulated Deficit | $(590,652) | $(537,346) |
Revenue by Geography (2025): U.S. ($51.9 million, 92% of total); Europe ($4.8 million, 8% of total).
Units Sold: 1,648 units in the U.S. and 219 units in Europe.
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased 10% year-over-year, driven by expansion into new sales territories (53 territories in 2025 vs. 48 in 2024) and increased active implanting centers (252 vs. 223).
- Profitability Improvement: Net loss narrowed by 11% to $53.3 million, primarily due to a 3% reduction in Selling, General, and Administrative (SG&A) expenses.
- SG&A Reduction: SG&A expenses decreased by $2.8 million, largely attributed to a $7.9 million decrease in non-cash stock-based compensation (related to the modification of the former CEO's stock options in 2024).
- Interest Expense: Interest expense increased 33% to $5.8 million due to borrowings under the Term Loan Agreement.
- Cash Position: Cash and cash equivalents decreased by $30.2 million, reflecting net cash used in operating activities of $40.2 million, partially offset by financing activities.
Guidance, Outlook, and Risks
Outlook and Recent Developments:
- Debt Facility Expansion: In January 2026, the company amended its Loan Agreement to increase available term loans to $100 million (from $50 million) and extended the maturity date to 2031. An additional $10 million was drawn immediately.
- ATM Offering: A new At-The-Market (ATM) sale agreement was entered into in January 2026, allowing for the sale of up to $50 million in common stock.
- Clinical Trials: The FDA granted an Investigational Device Exemption (IDE) in November 2025 for the BENEFIT-HF trial, a Phase III study evaluating Barostim in an expanded patient population. Enrollment began in January 2026.
- Reimbursement: New Category I CPT codes for Barostim took effect in January 2026, expected to improve prior authorization predictability and eliminate automatic denials associated with previous Category III codes.
Key Risks and Contingencies:
- Liquidity: The company has a history of significant losses and expects to continue incurring losses. It relies on existing cash, revenue, and access to its debt and equity facilities to fund operations for at least the next two years.
- Single Product Dependence: The business is highly dependent on the commercial success of Barostim. Failure to increase market acceptance or maintain reimbursement could materially harm operations.
- Regulatory and Clinical: Future growth depends on the success of the BENEFIT-HF trial and potential expansion of indications. Negative clinical results could impact adoption and regulatory status.
- Supply Chain: The company relies on a limited number of third-party suppliers for critical components, creating vulnerability to supply shortages.
Investor Verification Checklist
- Debt Covenants: Verify compliance with the performance covenants in the amended Loan Agreement, specifically the requirement to achieve 50% of the trailing twelve-month revenue target.
- Cash Burn Rate: Monitor the net cash used in operating activities ($40.2 million in 2025) against the current cash balance ($75.7 million) to assess runway without additional financing.
- Reimbursement Impact: Track the adoption rate of the new Category I CPT codes effective January 2026 and their effect on hospital ordering and prior authorization approval rates.
- Clinical Trial Progress: Monitor enrollment rates and interim data from the BENEFIT-HF trial, which is critical for expanding the addressable market from ~339,000 to ~983,000 patients.
- Stock-Based Compensation: Review future stock-based compensation expenses, noting the significant reduction in 2025 was partially due to a one-time modification of the former CEO's options in 2024.